Karyopharm Therapeutics (KPTI) Other Accumulated Expenses (2012 - 2026)

Karyopharm Therapeutics (KPTI) has 14 years of Other Accumulated Expenses data on file, last reported at $4.6 million in Q4 2025.

• Quarterly Other Accumulated Expenses rose 181.11% year-over-year to $4.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $4.6 million (up 181.11% YoY) and the FY2025 annual result came in at $4.6 million, up 181.11% from the prior year.
• Other Accumulated Expenses improved to $4.6 million in Q4 2025, from $1.8 million in the prior quarter.
• In the past five years, Other Accumulated Expenses ranged from a high of $7.1 million in Q4 2023 to a low of $524000.0 in Q2 2021.
• A 5-year average of $2.4 million and a median of $1.9 million in 2022 frame the typical range for Other Accumulated Expenses.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses surged 844.99% — and 2024, when it tumbled 76.96%.
• Tracing KPTI's Other Accumulated Expenses over 5 years: stood at $678000.0 in 2021, then surged by 844.99% to $6.4 million in 2022, then advanced by 11.18% to $7.1 million in 2023, then plunged by 76.96% to $1.6 million in 2024, then jumped by 181.11% to $4.6 million in 2025.
• The last three Other Accumulated Expenses figures came in at $4.6 million (Q4 2025), $1.8 million (Q3 2025), and $1.6 million (Q2 2025), per Business Quant data.